An open-label, 2 part study to investigate the pharmacokinetics, safety, and tolerability of MK0431(sitagliptin phosphate) in patients with varying degrees of renal insufficiency

Trial Profile

An open-label, 2 part study to investigate the pharmacokinetics, safety, and tolerability of MK0431(sitagliptin phosphate) in patients with varying degrees of renal insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2007

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top